Aryl hydrocarbon receptor as a new therapeutic target for cancer and immune disorders

doi:10.5497/wjp.v2.i4.107

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10035)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

538

WORD

390

HTML

6075

Figures (1-2)

305

Tables (1-2)

261

Sum=7569

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1169

Download

1297

Sum=2466

Dec 9, 2013 (publication date) through Jan 13, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Pharmacology

ISSN

2220-3192

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Pharmacol. Dec 9, 2013; 2(4): 107-114
Published online Dec 9, 2013. doi: 10.5497/wjp.v2.i4.107

Full Size Figure Download Figure

Figure 1 Schematic representation of the functional domains of aryl hydrocarbon receptor. bHLH: Basic helix loop helix; PAS: Per-Arnt-Sim; TAD: Transcription activation domain; Q: Glutamine-rich region; DBD: DNA binding domain; LB: Ligand binding domain; ARNT: AhR nuclear translocator.

Citation: Vega L, Elizondo G. Aryl hydrocarbon receptor as a new therapeutic target for cancer and immune disorders. World J Pharmacol 2013; 2(4): 107-114
URL: https://www.wjgnet.com/2220-3192/full/v2/i4/107.htm
DOI: https://dx.doi.org/10.5497/wjp.v2.i4.107